Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verve Therapeutics, Inc.

http://www.vervetx.com

Latest From Verve Therapeutics, Inc.

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Deals M & A

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

The company claims its gene editing tech is the most potent yet – and is joining others in making established cardiovascular disease gene PCSK9 its first therapeutic target

Companies Gene Therapy

Finance Watch: Stark Contrast As Big FOPOs Reach Market, Other Firms Cut Costs

Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.

Financing Business Strategies

The New Antibodies Revolutionizing Medicine

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Innovation Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register